# General Psychiatry in Primary Care: Depression and Anxiety

Julia N. Riddle, MD

Assistant Professor Center for Women's Mood Disorders **UNC School of Medicine** Department of Psychiatry Chapel Hill, NC



CONTINUING EDUCATION COMPANY

## Disclosure

Advisory Board: Cercle.ai


Ownership Interest: Cercle.ai

CONTINUING EDUCATION COMPANY

# Learning Objectives

- 1. Appreciate the continued expanding role of primary care providers in screening, diagnosis, and treatment of mental illness.
- 2. Understand best practices for treating depression and anxiety.
- 3. Discuss referring to mental healthcare, setting boundaries, and crisis planning.

CONTINUING EDUCATION COMPANY



## Primary Care as the Front Line

#### DUH, BUT WHY?!?!


- Limited insurance coverage for mental healthcare
- Shortage of psychiatric clinicians (regardless of quality)
- Stigma
- Improvement in treatments
  - SSRIs are safer and more tolerable
- The internet, always the internet.

5


## Common Questions/Concerns


- What medication to start?
- When to change?
- When to augment?
- When to refer?
- How to not exhausted myself caring for these patients?

First some background....



Epidemiology				
Disorder/Syndrome	12 month - Men	12 month - Women	Lifetime	
Major Depressive Disorder (MDD) - Men	7%	13%	15-26%	
Suicide attempts w/in an MDD episode	13.	62%	4.77%	
Anxiety Disorders (GAD, PD, OCD, PTSD, etc)	14.3%	23.4%	19.1%	
Bipolar Disorder	2.9%	2.8%	4.4%	
Schizophrenia and related psychotic dis.			0.25 - 0.64%	
ADHD – Adults			4.4% (or 14-26%)	






## Screening

#### **Depression**

- Patient Health Questionnaire (PHQ-9)
- Quick Inventory of Depressive Symptomatology – Self-Report (QIDS-SR)
- Edinburgh Postnatal Depression Scale (EPDS)

#### **Anxiety**

- Generalized Anxiety Disorder Scale – 7 (GAD-7)
- Geriatric Anxiety Scale (GAS)
- Edinburgh Postnatal Depression Scale (EPDS, qs 3-5)



### Assessment

#### History

- Family History
- Medication History
- Hospitalizations
- Suicide Attempts
- Trauma History

#### Physical Work-up/Baseline

- Weight
- BP
- TSH
- · CBC/CMP
- EKG/Qtc

### Assessment

- Appearance
- Behavior
- Mood
- Affect
- Motor
- Speech
- Thought process and content
- Perception
- Cognition
- Insight
- Judgment

Assessment is not the same as recording a patient report.

15

# Diagnosis: Perspectives


- Disease: what someone has
- Dimension: who someone is
- Behavior: what someone *does*
- Life Story: what someone has *experienced*
- Developmental?

Peters ME, Taylor J, Lyketsos CG, Chisolm MS. Beyond the DSM: the perspectives of psychiatry approach to patients. Prim Care Companion CNS Disord 2012;14(1):PCC.11m01233. doi:10.4088/PCC.11m01233. Epub 2012 Feb 23. PMID: 22690367;PMCID: PMC3357579.
MCHuldh Paul R. and Phillin R. Slaveny. The perspectives of psychiatry. JHILL Press. 1998.

# Diagnosis: Perspectives

#### Consider:

- Suicidal ideation
- Changes in concentration/distraction
- Disease: what someone has
- Dimension: who someone is
- Behavior: what someone does
- Life Story: what someone has experienced



### Before Treatment: Setting Expectations

- Medication doses
- Early side effects
- Role of therapy
- Early referral
- Follow-up
- Crisis Planning

Boundaries & Expectations

19

### Treatment Dose Ranges-SSRI

	Starting Dose (to mitigate side effects)	MDD/PPD*	Anxiety Disorders***	OCD***
Sertraline	25-50 mg	100 – 200 mg	100-200 mg	200-400 mg
Fluoxetine	10 mg	20 – 60 mg	20-60 mg	40-100 mg
Escitalopram	5-10 mg HS	10-20 mg	20-40 mg	20-60 mg**
Citalopram	10 mg	20-40 mg	20-40 mg	20-80 mg**
Fluvoxamine	50-100 mg HS			100-300 mg
Paroxetine	10-20 mg	50 mg	60 mg	60 mg

\*No SSRI/SNRI has been FDA approved for PPD/PPA

\*\*Off-label use

\*\*\*Often above FDA-approved maximum recommended dose

Side Effects - SSRI		
	Most Common Side Effects (>5% and 2x placebo)	
Sertraline	Nausea, diarrhea, tremor, dyspepsia, sweating, low appetite, ejaculation failure (ED), decrease libido (>5%)	
Fluoxetine	Nausea, diarrhea, constipation, insomnia, low appetite, dry mouth, increased anxiety early on, sweating, ED, tremor	
Escitalopram	Fatigue/somnolence, insomnia, decreased libido, anorgasmia, nausea, sweating, QTc prolongation (over others)	
Citalopram	Insomnia, ED, sweating, fatigue/somnolence, decreased libido, anorgasmia, more QTc prolongation than others	
Fluvoxamine	nausea, somnolence, insomnia, nervousness, dyspepsia, ED, sweating, tremor, vomiting, anorgasmia, decreased libido, dry mouth, rhinitis, taste perversion, and urinary frequency in patients with OCD	

## Treatment Dose Ranges- More

	Starting Dose (to mitigate side effects)	MDD	Anxiety Disorders
Bupropion XL	150 mg	300 – 450 mg	
Venlafaxine	37.5-75 mg	150 – 225 mg	225 mg
Duloxetine	30 – 60 mg	60 – 120 mg	60 - 120 mg
Vilazodone	10 mg	40 mg	
Nortriptyline	10-25 mg	75 – 100 mg (level)	

### Side Effects - SSRI

	Most Common Side Effects (>5% and 2x placebo)
Bupropion XL	Insomnia, slight QTc prolongation
Venlafaxine	Drowsiness, insomnia, GI, sexual side effects
Duloxetine	Insomnia/agitation, GI, unclear weight gain, sexual dysfunction
Vilazodone	Insomnia/agitation, GI, sexual dysfunction
Nortriptyline	Anticholinergic, drowsiness, orthostatic hypotension, slight weight gain

23

### Tell Me More: Libido

- Most SSRIs are equal in sexual side effects (paroxetine worse)
- Venlafaxine more sexual side effects
- Mirtazapine, duloxetine, vilazodone, vortioxetine all low sexual SE
- Bupropion almost none (never say never)


## Tell Me More: Weight Gain

- Paroxetine and mirtazapine = more
- SSRIs (except fluoxetine) = slight
- Duloxetine, venlafaxine = slight
- Bupropion: None

25


## Therapy + Meds = More Effective

- Behavioral Therapy
- Cognitive Behavioral Therapy (CBT)
- Interpersonal Psychotherapy (IPT)
- Psychodynamic Therapy
- Dialectical Behavioral Therapy (DBT)
- Exposure Response Therapy
- Supportive Therapy




### Re-assessment

- Get to optimal dose (not starting dose) x 6-8 weeks
- Compare screening scales
- Bring a partner/friend to visit to provide realtime collateral
- Reinforce therapy
- Refer




# Augmentation

- Bupropion
- Trazodone
- Second generation antipsychotics
  - Ariprazole, olanzapine, quetiapine, risperidone, ziprasidone
- Buspirone
- Lamotrigine
- Lithium



## Referral/Structure

- If moderate-severe symptoms: refer early
- Access to more treatment modalities
- Communication/relationship with mental health providers
- Collaborative Care Models
- Imbedded Consultation Models



# **Setting Boundaries**

- Do not fear setting boundaries!
- Vital for patient's care and your own
- We can't leave Freud completely out:
  - Transference
  - Countertransference
- Expectations around when to message and when you will respond
- Reinforce to patient (and yourself) that remission takes time
- Crisis plan for psychiatric emergency



"And you're honestly not feeling any transference?"

### Crisis Plan

- Create a smartphrase/print out
  - Suicide Hotline: 988
  - Chat: www.988lifeline.org
  - Local emergency rooms
  - Link to a safety planning tool: Stanley Brown Safety Plan
  - Starter instructions for finding therapist
    - Get list from insurance
    - PsychologyToday.com
    - · Info for local mental health care

STANLEY - BROWN SAFETY PLAN	
STEP 1: WARNING SIGNS:	
1,	
2.	
3.	
STEP 2: INTERNAL COPING STRATEGIES – THINGS I CAN DO TO TAKE MY MIND OFF MY PROBLEMS WITHOUT CONTACTING ANOTHER PERSON:	
1,	l .
2.	
3.	
STEP 3: PEOPLE AND SOCIAL SETTINGS THAT PROVIDE DISTRACTION:	l
1. Name: Contact:	ı
2. Name: Contact:	
3. Place: 4. Place:	
STEP 4: PEOPLE WHOM I CAN ASK FOR HELP DURING A CRISIS:	l .
1. Name: Contact:	l e e e e e e e e e e e e e e e e e e e
2. Name: Contact:	
3. Name: Contact:	
STEP 5: PROFESSIONALS OR AGENCIES I CAN CONTACT DURING A CRISIS:	ı
1. Clinician/Agency Name: Phone:	
Emergency Contact:	
Emergency Contact:	
3. Local Emergency Department:	
Emergency Department Address:	
Emergency Department Phone :	
4. Suicide Prevention Lifeline Phone: 1-800-273-TALK (8255)	•
STEP 6: MAKING THE ENVIRONMENT SAFER (PLAN FOR LETHAL MEANS SAFETY):	
h	
2.	
The Standey-Brown Sufery Flam is experighted by Barbara Stanley, PhD & Gregory K. Brown, PhD (2008, 2021).  Individual use of the Stanley-Brown Sufery Flam form is permitted. Written permitted proon the authors is required for any changes to this form or use of this form in the electronic medical coverd. Additional necessary are available from www.neis/calcular.ne.	
Stanley-Brown safety Planning Intervention	

### Other Treatments

- Electroconvulsive Therapy (ECT)
- Transcranial Magnetic Stimulation (TMS)
- Esketamine (intranasal)
- Brexanolone
- Zuranolone

37

# Thank you!

• Question?

US Preventive Services Task Force:

https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adultsscreening

Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry. 2009 Sep;70(9):1219-29. doi: 10.4088/JCP.09r05021. PMID: 19818243.

Abed Faghri NM, Boisvert CM, Faghri S. Understanding the expanding role of primary care physicians (PCPs) to primary psychiatric care physicians (PPCPs): enhancing the assessment and treatment of psychiatric conditions. Ment Health Fam Med. 2010 Mar;7(1):17-25. PMID: 22477919;

Anthony JS, Baik SY, Bowers BJ, Tidjani B, Jacobson CJ, Susman J. Conditions that influence a primary care clinician's decision to refer patients for depression care. Rehabil Nurs, 2010 May-Jun;35(3):113-22. doi: 10.1002/j.2048-7940.2010.tb00286.x. PMID: 20450020;

Hirschfeld, R. M. (2012). Depression epidemiology and its treatment evolution. The Journal of clinical psychiatry, 73(10), 27626.

39

#### What Percentage of Patients with Depression **Receive Psychiatric Medications from Their PCP?**

A. 30%

B. 55%

C. 75%

D. 90%

1987 to 1997:

37.3% → 74.5%

-Faghri, et al. 2010